Evidence map›Paper›PMID 41735302›Full record

ArticleNature communications2026

Conformational landscape of HIV-1 Env from closed to fully open.

Jiayan Cui, Zi Jie Lin, Sukanya Ghosh, Jianqiu Du, Roopak Sadeesh, David B Weiner, Jesper Pallesen

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiayan CuiVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Zi Jie Lin *Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0004-1707-6471
Sukanya Ghosh *Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
Jianqiu Du *Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0001-2626-6590
Roopak SadeeshVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
David B WeinerVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-2232-8512
Jesper PallesenVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA. jpallesen@wistar.org.ORCID http://orcid.org/0000-0002-3270-1587

Funding

Vaccine and adjuvant Clinical GMP product development and DNA Technology platform enhancementsU19AI166916 · NIAID · WISTAR INSTITUTE · PI DAVID B. WEINER · 2023 to 2026
$24.0M
NIAID NIH HHS U19 AI166916W. W. Smith Charitable Trust A2404
6 · The paper itself

Abstract

The molecular mechanism of HIV-1 entry into host cells is governed by dynamic conformational changes to its envelope glycoprotein (Env), which are triggered by the engagement of the host receptor CD4 and coreceptors. Structural insights into these transitions have been advanced by cryo-electron tomography (cryo-ET), resolving Env structures in closed and multifarious open states within native membranes, and by cryo-electron microscopy (cryo-EM), which has provided atomic details of these states. In this study, we determine cryo-EM structures of soluble native-like Env in complex with antibody 3BC315, antibody b12, CD4, or a combination of 3BC315 and b12, capturing previously uncharacterized conformational states. Observing enhanced 3BC315 binding occupancy in the presence of b12, we investigate the cooperativity of these antibodies using mass photometry and neutralization assays. Integrating these states with the literature, we establish a classification framework for symmetric and asymmetric Env states, categorizing by their degree of openness and stepwise structural rearrangements. Our findings refine the mechanistic understanding of HIV-1 Env dynamics and provide a structural roadmap for targeting dynamic Env states to develop more potent vaccines and immunotherapies.

Indexed as

env Gene Products, Human Immunodeficiency VirusHIV-1Antibodies, NeutralizingCD4 AntigensCryoelectron MicroscopyHIV AntibodiesHumansModels, MolecularProtein ConformationAntibodies, NeutralizingCD4 Antigensenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID41735302
PMCPMC13168245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.